UNKNOWN PARIETEX PRODUCT
Report
- Report Number
- 9615742-2021-01392
- Event Type
- Injury
- Date Received
- May 27, 2021
- Date of Event
- July 14, 2020
- Report Date
- May 26, 2021
- Manufacturer
- SOFRADIM PRODUCTION SAS
- Product Code
- FTL
- Adverse Event
- Yes
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- UK
- Reporter Occupation
- OTHER
Narratives
TITLE: TOTAL ENDOSCOPIC-ASSISTED LINEA ALBA RECONSTRUCTION (TESLAR) FOR TREATMENT OF UMBILICAL/PARAUMBILICAL HERNIA AND RECTUS ABDOMINUS DIASTASIS IS ASSOCIATED WITH UNACCEPTABLE PERSISTENT SEROMA FORMATION: A SINGLE CENTRE EXPERIENCE SOURCE: HERNIA (2020) 24:1379¿1385 HTTPS://DOI.ORG/10.1007/S10029-020-02266-8 RECEIVED: 20 MAY 2020 / ACCEPTED: 14 JULY 2020 / PUBLISHED ONLINE: 20 JULY 2020 © SPRINGER-VERLAG FRANCE SAS, PART OF SPRINGER NATURE 2020. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
ACCORDING TO LITERATURE SOURCE OF STUDY PERFORMED BETWEEN MARCH 2018 AND MAY 2019, TOTAL ENDOSCOPIC-ASSISTED LINEA ALBA RECONSTRUCTION WAS PERFORMED TO 21 PATIENTS AND PARIETEX WAS USED TO 3 PATIENTS. THE AIM OF THE STUDY WAS TO ESTABLISH THE RISKS AND BENEFITS OF SAFELY PERFORMING TOTAL ENDOSCOPIC-ASSISTED LINEA ALBA RECONSTRUCTION. ONE PATIENT SUFFERED FROM SEVERE POSTOPERATIVE INFECTED COLLECTION FOLLOWING THE PROCEDURE WHICH REQUIRED FORMAL WASHOUT AND REMOVAL OF THE MESH. OTHER POSTOPERATIVE COMPLICATIONS INCLUDE: SEROMA, CHRONIC PAIN, AND RECURRENCE. PATIENTS WITH SEROMAS UNDERWENT ASPIRATIONS AND REOPERATION.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 791837 | UNKNOWN PARIETEX PRODUCT | FTL | SOFRADIM PRODUCTION SAS | UNKNOWN PARIETEX PRODUCT |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Hospitalization| R |